Organogenesis Holdings (ORGO) Liabilities and Shareholders Equity (2015 - 2026)

Organogenesis Holdings' Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $520.0 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 11.25% year-over-year to $520.0 million; the TTM figure through Mar 2026 stood at $2.1 billion (up 12.67% YoY), while the FY2025 annual figure was $598.7 million, up 20.25% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $520.0 million, down from $598.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $598.7 million in Q4 2025, with the low at $436.3 million in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $458.5 million (2024), against an average of $471.8 million.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 36.68% in 2022, then dropped 3.53% in 2024.
• Organogenesis Holdings' Liabilities and Shareholders Equity stood at $449.4 million in 2022, then grew by 2.37% to $460.0 million in 2023, then climbed by 8.23% to $497.9 million in 2024, then gained by 20.25% to $598.7 million in 2025, then fell by 13.15% to $520.0 million in 2026.
• Business Quant data shows ORGO's Liabilities and Shareholders Equity at $520.0 million in Q1 2026, $598.7 million in Q4 2025, and $509.8 million in Q3 2025.